InNexus Biotechnology Inc. and XERIS Pharmaceuticals, Inc. announced a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus’ Dynamic Cross Linking (DXL) antibodies using XERIS’ proprietary formulation-injection technologies.

“We see a need for an improved delivery system for antibodies that enables self injection of these important therapeutic agents, by patients at home,” said John Kinzell, CEO of XERIS. “Our delivery system addresses a number of major issues related to storing and administering antibodies and is suitable for and could add value in both chronic and acute therapies.”

Jeff Morhet, CEO of InNexus said, “We continue to demonstrate applicability of our DXL technology to a variety of disease targets and we are excited to work with XERIS to identify DXL antibodies which are suitable for subcutaneous delivery to patients using XERIS formulation-injection technology. Antibodies are the leading choice of pharmaceutical companies for drug development and we will continue to position InNexus and our technology to take advantage or the industry’s growth. This collaboration is novel and showcases two dynamic technologies.”

InNexus Biotechnology Inc. is a public biotechnology company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency and safety of existing antibody products, thus expanding their usefulness, enabling new disease applications and opening new markets.

XERIS is an early-stage, specialty biopharmaceutical company developing patient-friendly injectables to treat endocrine and metabolic diseases. The company's formulation-injection technologies allow the subcutaneous delivery of highly concentrated, semi-solid formulations of all drug classes, including small molecules, peptides, proteins, antibodies, and nucleotide-based therapeutics.